Therapeutic induction of angiogenesis by direct myocardial administration of an adenovirus vector encoding human hepatocyte growth factor gene and its safety
- 11 Downloads
After the study in vitro and in rats, we assessed further the effects and safety of local angiogen therapy using intramyocardial delivery of an adenovirus carrying hepatocyte growth factor gene (Ad-HGF) in a canine ischemia model. The angiogenic activity of Ad-HGF was evaluated from three aspects. First, the augmentation of collateral vessel development was assessed by angiography 30 d after surgery. The results showed that the density of collateral vessels in treated group was higher than that of control group. Secondly, infarct size was evaluated by TTC staining and image analysis. The results showed that the infarct size of treated group was smaller than that of control group. Thirdly, the myocardial regional blood flow was determined by the method of colored microspheres. The results showed that the blood flow recovered to the level before ligation in treated group, but that of the control group was lower than normal level. In addition, during the study of chronic toxicity, we tested the anti-adenovirus antibodies by neutralization method. The antibodies yielded after the fourth injection decreased slowly from peak level and disappeared 12 weeks after drug withdrawal. Overall, Ad-HGF can promote angiogenesis in ischemic myocardium and reduce infarct size. So this method may be considered as a therapeutic angiogenesis induction strategy for ischemic disease including myocardial infarction and peripheral artery disease. At the same time, Ad-HGF could induce the yield of anti-adenovirus antibodies to neutralize adenovirus, which may be the mechanism of adenovirus clearance.
Keywordsmyocardial ischemia gene therapy recombinant adenovirus hepatocyte growth factor neutralizing antibody
Unable to display preview. Download preview PDF.
- 9.Tanaka, M., Brooks, S. E., Richard, V. J. et al., Effect of anti-CD18 antibody on myocardial neutrophil accumulation and infarct size after 90 minutes of ischemia and 3 hours of reperfusion in dogs, Circulation, 1993, 87(2): 526–535.Google Scholar
- 10.Kowallik, P., Schulz, R., Guth, B. D. et al., Measurement of regional myocardial blood flow with multiple colored microspheres, Circulation, 1991, 83(3): 974–982.Google Scholar
- 13.Simons, M., Annex, B., A double-blind, placebo-controlled, dose escalation phase I study to assess the safety and effects of AMG0001 in patients with ischemic heart disease (IHD) not amenable to coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI), Recombinant DNA Advisory Committee, 2002,: 20–23.Google Scholar